{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:54:53Z","timestamp":1781250893536,"version":"3.54.1"},"reference-count":64,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/17474086.2020.1770590","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T12:40:51Z","timestamp":1591015251000},"page":"745-753","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy"],"prefix":"10.1080","volume":"13","author":[{"given":"Avyakta","family":"Kallam","sequence":"first","affiliation":[{"name":"Division of Oncology\/Hematology, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"Division of Oncology\/Hematology, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"issue":"11","key":"cit0001","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin\u2019s Lymphoma","year":"1997","journal-title":"Blood"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821015)50:8<1539::AID-CNCR2820500814>3.0.CO;2-G"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/72.4.540"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"cit0005","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH.","year":"2017"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-170-7_2"},{"key":"cit0007","unstructured":"SEER database. SEER cancer stat. 2019;2020(January 2)."},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_1"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0267-0"},{"issue":"1","key":"cit0010","first-page":"76","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"issue":"8","key":"cit0015","volume":"29","author":"Lunning MA","year":"2015","journal-title":"Oncology"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg702"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.009"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25463"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008409601731"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1002\/hon.151_2631"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56891-0"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903580402"},{"issue":"5","key":"cit0035","first-page":"702","volume":"90","author":"Zinzani PL","year":"2005","journal-title":"Haematologica"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111708"},{"issue":"21","key":"cit0037","first-page":"2305","volume":"132","author":"Lemonnier F","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2009-0"},{"key":"cit0040","doi-asserted-by":"crossref","unstructured":"William BM, Huang Y, Johnson A, et al. No title. Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r\/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial; 2019.","DOI":"10.1016\/j.clml.2019.07.384"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470"},{"key":"cit0042","doi-asserted-by":"crossref","unstructured":"Iyer SP, Haverkos BM, Zain J, et al. No title. Final Results of Phase 1\/1b Study of Tenalisib, Dual PI3K \u03b4\/\u03b3 Inhibitor in Patients with Relapsed\/Refractory T-Cell Lymphoma; 2019.","DOI":"10.1182\/blood-2019-123954"},{"key":"cit0043","unstructured":"Oki Y, Zain J, Haverkos BM, et al. No title. Safety and Anti-Tumour Activity of RP6530, Dual PI3K \u03b4\/\u03b3 Inhibitor, in Relapsed\/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I\/Ib Study; 2017."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.77"},{"key":"cit0045","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Feldman TA, Hess BT, et al. No title. The novel SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed\/refractory peripheral T-Cell lymphoma and cutaneous T-cell lymphoma; 2018.","DOI":"10.1182\/blood-2018-99-119944"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"cit0047","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Coiffier B, Radford J, et al. No title. A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral T-cell lymphoma (PTCL); 2014.","DOI":"10.1182\/blood.V124.21.1763.1763"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1536"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S140756"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3418-2"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.022"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2438_117"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2249"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806737"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13566"},{"key":"cit0058","unstructured":"Falchi L, Lue JK, Amengual JE, et al. A phase 1\/2 study of oral 5-azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T-cell lymphoma (PTCL); 2017."},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-007-0260-8"},{"key":"cit0060","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Koch R, Mehta-Shah N, et al. In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, in combination with romidepsin or bortezomib in relapsed\/refractory T-cell lymphoma; 2017.","DOI":"10.1182\/blood.V130.Suppl_1.819.819"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0232-x"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.013"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.645818"},{"key":"cit0064","volume-title":"Anti-lymphoma activity of lacutamab(IPH4102), first in class anti- KIR3DL2 antibody, is augmented by PTCL chemotherapies","author":"Paturel C","year":"2020"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2020.1770590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T12:57:49Z","timestamp":1620478669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2020.1770590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/17474086.2020.1770590"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2020.1770590","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}